Hologic, Inc. (NASDAQ:HOLX) Short Interest Update

Hologic, Inc. (NASDAQ:HOLX) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 7,100,246 shares, a decline of 14.5% from the February 26th total of 8,301,510 shares. Currently, 3.2% of the company’s stock are sold short. Based on an average trading volume of 2,957,823 shares, the days-to-cover ratio is presently 2.4 days.

Analyst Ratings Changes

A number of research firms have recently weighed in on HOLX. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and cut their target price for the company from $79.00 to $78.00 in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $78.42.

Institutional Investors Weigh In On Hologic

A number of hedge funds have recently bought and sold shares of the company. NewEdge Wealth LLC lifted its position in shares of Hologic by 3.8% during the 3rd quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after purchasing an additional 138 shares during the last quarter. Allworth Financial LP grew its holdings in Hologic by 8.1% in the 4th quarter. Allworth Financial LP now owns 1,890 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 141 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in Hologic by 1.9% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 7,675 shares of the medical equipment provider’s stock worth $572,000 after buying an additional 142 shares during the period. BCS Private Wealth Management Inc. increased its position in Hologic by 2.5% in the 4th quarter. BCS Private Wealth Management Inc. now owns 6,105 shares of the medical equipment provider’s stock worth $455,000 after buying an additional 150 shares during the period. Finally, Savant Capital LLC lifted its holdings in shares of Hologic by 0.9% during the third quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock worth $1,335,000 after buying an additional 170 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Hologic stock traded up $0.03 during trading hours on Tuesday, reaching $75.58. 848,966 shares of the company were exchanged, compared to its average volume of 2,766,976. Hologic has a 12 month low of $51.90 and a 12 month high of $75.78. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average of $75.24 and a 200 day moving average of $73.41. The firm has a market cap of $16.87 billion, a price-to-earnings ratio of 31.49, a PEG ratio of 2.25 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 earnings per share. As a group, research analysts anticipate that Hologic will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.